MCID: ACT098
MIFTS: 59

Acute Erythroid Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Acute Erythroid Leukemia

MalaCards integrated aliases for Acute Erythroid Leukemia:

Name: Acute Erythroid Leukemia 11 19 58 14 36 75
Acute Erythroleukemia 19 16 71
Acute Myeloid Leukemia Fab-M6 19 71
Acute Myeloid Leukemia M6 19 58
Erythroleukemia 19 58
Aml M6 19 58
Acute Erythroid Leukaemia Without Mention of Remission 33
Acute Erythraemia and Erythroleukaemia 33
Acute Erythroleukemia - M6a Subtype 71
Acute Erythroleukemia - M6b Subtype 71
Acute Erythroleukemia M6a Subtype 19
Acute Erythroleukemia M6b Subtype 19
Acute Myeloid Leukemia, M6 Type 28
Acute Erythroblastic Leukemia 71
Acute Erythraemic Myelosis 33
Di Guglielmo's Syndrome 19
Di Guglielmo Syndrome 19
Erythraemic Myelosis 33
Acute Erythraemia 33
Erythroleukaemia 33
Erythraemia 33
Aml-M6 19

Characteristics:


Age Of Onset:

Adolescent,Adult,Childhood,Elderly 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0080780
NCIt 49 C8923
ICD10 31 C94.0
ICD10 via Orphanet 32 C94.0
UMLS via Orphanet 72 C0023440
Orphanet 58 ORPHA318
ICD11 33 631263622
UMLS 71 C0023440 C2930974 C2930975 more

Summaries for Acute Erythroid Leukemia

GARD: 19 A rare unclassified acute myeloid leukemia characterized by a proliferation of immature cells exclusively of the erythroid lineage without a significant myeloblastic component. Microscopically, the cells may be undifferentiated or proerythroblastic in appearance. Patients may present with pancytopenia with fatigue, infections, and mucocutaneous bleedings, as well as weight loss, fever, and night sweats. Prognosis is poor.

MalaCards based summary: Acute Erythroid Leukemia, also known as acute erythroleukemia, is related to erythroleukemia and polycythemia. An important gene associated with Acute Erythroid Leukemia is H2AC18 (H2A Clustered Histone 18), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Assembly of the pre-replicative complex. The drugs Cyclophosphamide and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related phenotypes are anemia and pancytopenia

Orphanet: 58 A rare unclassified acute myeloid leukemia characterized by a proliferation of immature cells exclusively of the erythroid lineage without a significant myeloblastic component. Microscopically, the cells may be undifferentiated or proerythroblastic in appearance. Patients may present with pancytopenia with fatigue, infections, and mucocutaneous bleedings, as well as weight loss, fever, and night sweats. Prognosis is poor.

Disease Ontology: 11 An acute myeloid leukemia that is characterized by a predominant immature erythroid population.

Wikipedia: 75 Acute erythrocyte leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where... more...

Related Diseases for Acute Erythroid Leukemia

Diseases related to Acute Erythroid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 erythroleukemia 31.6 TFRC TAL1 SPI1 NPTN MYB KLF1
2 polycythemia 30.9 TFRC JAK2 IL3 GATA1 EPOR EPO
3 refractory anemia with excess blasts 30.8 U2AF1 GATA2
4 thalassemia 30.6 TFRC KLF1 GATA1 EPO
5 pancytopenia 30.5 U2AF1 IL3 H2AC18 EPO CD34
6 mast cell neoplasm 30.5 U2AF1 IL3 H2AC18
7 acute leukemia 30.4 TAL1 JAK2 IL3 GATA2 GATA1 EPO
8 mastocytosis, cutaneous 30.4 U2AF1 IL3 CD34
9 hematologic cancer 30.3 U2AF1 MIR92A1 KDM4C JAK2 IL3 H2AC18
10 thrombocytosis 30.3 U2AF1 JAK2 IL3 EPO
11 acute megakaryocytic leukemia 30.3 U2AF1 JAK2 IL3 GATA2 GATA1 EPOR
12 myeloproliferative neoplasm 30.3 U2AF1 KDM4C JAK2 IL3 H2AC18 GATA1
13 gastrointestinal stromal tumor 30.2 U2AF1 JAK2 H2AC18 CD34
14 precursor t-cell acute lymphoblastic leukemia 30.2 TAL1 MYB CD34
15 hemoglobinopathy 30.2 TFRC KLF1 IL3 GYPA GATA1 EPOR
16 myelodysplastic syndrome 30.2 U2AF1 TFRC MYB KDM4C JAK2 IL3
17 alpha-thalassemia 30.2 TFRC KLF1 H2AC18 GATA1 EPO
18 aplastic anemia 30.2 U2AF1 TFRC IL3 H2AC18 GATA2 GATA1
19 polycythemia vera 30.2 U2AF1 TFRC KDM4C JAK2 IL3 EPOR
20 fanconi anemia, complementation group a 30.2 U2AF1 IL3 H2AC18 GATA2 CD34
21 pure red-cell aplasia 30.2 U2AF1 EPOR EPO
22 lymphoma, hodgkin, classic 30.2 SPI1 KDM4C JAK2 IL3 H2AC18
23 myeloid leukemia 30.2 U2AF1 MYB JAK2 IL3 GATA2
24 hemolytic anemia 30.1 U2AF1 TFRC KLF1 H2AC18 GYPA GATA1
25 myeloma, multiple 30.1 U2AF1 TFRC KDM4C JAK2 IL3 H2AC18
26 anemia, sideroblastic, 1 30.1 TFRC KLF1 GATA1 EPO
27 myeloproliferative syndrome, transient 30.0 U2AF1 GYPA GATA2 GATA1 CD34
28 chronic leukemia 30.0 U2AF1 KDM4C JAK2 H2AC18 CD34
29 neutropenia 30.0 TFRC JAK2 IL3 EPO
30 t-cell acute lymphoblastic leukemia 30.0 U2AF1 TFRC TAL1 SPI1 MYB KDM4C
31 hereditary spherocytosis 30.0 TFRC KLF1 GYPA GATA1 EPO
32 leukemia, chronic lymphocytic 30.0 U2AF1 TFRC MYB MIR92A1 KDM4C JAK2
33 leukemia, acute myeloid 30.0 U2AF1 TFRC TAL1 SPI1 MYB MIR92A1
34 acute promyelocytic leukemia 29.9 U2AF1 SPI1 KDM4C IL3 H2AC18 GATA2
35 myelofibrosis 29.8 U2AF1 MYB JAK2 IL3 GATA2 GATA1
36 sickle cell anemia 29.8 TFRC KLF1 H2AC18 GYPA GATA1 EPO
37 chronic myelomonocytic leukemia 29.7 U2AF1 KDM4C JAK2 IL3 H2AC18 GATA2
38 essential thrombocythemia 29.7 U2AF1 JAK2 IL3 H2AC18 GATA1 EPOR
39 leukemia, chronic myeloid 29.7 U2AF1 TAL1 MYB MIR92A1 KDM4C JAK2
40 thrombocytopenia 29.6 U2AF1 TFRC KLF1 JAK2 IL3 GATA2
41 leukemia, acute lymphoblastic 29.6 U2AF1 TAL1 MYB KDM4C JAK2 IL3
42 deficiency anemia 29.6 U2AF1 TFRC MYB KLF1 JAK2 IL3
43 beta-thalassemia 29.5 TFRC MYB KLF1 JAK2 IL3 GATA2
44 erythroleukemia, familial 11.6
45 leukemia 10.6
46 acute myeloid leukemia with recurrent genetic anomaly 10.5
47 refractory cytopenia with multilineage dysplasia 10.4 U2AF1 GATA2
48 epiglottis cancer 10.4 EPO CD34
49 progressive myoclonus epilepsy 9 10.4 EPOR EPO
50 estrogen-receptor positive breast cancer 10.4 U2AF1 KDM4C H2AC18

Graphical network of the top 20 diseases related to Acute Erythroid Leukemia:



Diseases related to Acute Erythroid Leukemia

Symptoms & Phenotypes for Acute Erythroid Leukemia

Human phenotypes related to Acute Erythroid Leukemia:

58 30 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001903
2 pancytopenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001876
3 leukopenia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001882
4 refractory anemia with ringed sideroblasts 58 30 Frequent (33%) Frequent (79-30%)
HP:0004828
5 abnormal proerythroblast morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0025035
6 bone marrow hypercellularity 58 30 Frequent (33%) Frequent (79-30%)
HP:0031020
7 erythroid hypoplasia 58 30 Frequent (33%) Frequent (79-30%)
HP:0012133
8 bone marrow hypocellularity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005528

MGI Mouse Phenotypes related to Acute Erythroid Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CD34 EPO EPOR GATA1 GATA2 GPM6B
2 cellular MP:0005384 10.18 CD34 EPO EPOR GATA1 GATA2 GPM6B
3 liver/biliary system MP:0005370 10.11 EMB EPO EPOR GATA1 JAK2 KLF1
4 hematopoietic system MP:0005397 10.11 CD34 EPO EPOR GATA1 GATA2 GPM6B
5 cardiovascular system MP:0005385 10.1 EPO EPOR GATA1 GATA2 JAK2 MIR92A1
6 immune system MP:0005387 10.1 CD34 EPO EPOR GATA1 GPM6B IL3
7 embryo MP:0005380 10.06 EPO EPOR GATA1 GATA2 JAK2 KLF1
8 mortality/aging MP:0010768 9.86 EMB EPO EPOR GATA1 GATA2 GPM6B
9 integument MP:0010771 9.28 CD34 GATA1 JAK2 KDM4C KLF1 MYB

Drugs & Therapeutics for Acute Erythroid Leukemia

Drugs for Acute Erythroid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Busulfan Approved, Investigational Phase 3 55-98-1 2478
3
Aldesleukin Approved Phase 3 110942-02-4
4
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
5
Tioguanine Approved Phase 3 154-42-7 2723601
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
8
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
10
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
11
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
13
Daunorubicin Approved Phase 3 20830-81-3 30323
14
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
15
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Tipifarnib Investigational Phase 3 192185-72-1 159324
18 Alkylating Agents Phase 3
19 Antineoplastic Agents, Alkylating Phase 3
20 Anti-Retroviral Agents Phase 3
21 Interleukin-2 Phase 3
22 Anti-HIV Agents Phase 3
23 Analgesics, Non-Narcotic Phase 3
24 N-Methylaspartate Phase 3
25 Folic Acid Antagonists Phase 3
26 Antineoplastic Agents, Hormonal Phase 3
27 Folate Phase 3
28 Vitamin B9 Phase 3
29 Vitamin B Complex Phase 3
30 Hormone Antagonists Phase 3
31 Antiemetics Phase 3
32 Anti-Inflammatory Agents Phase 3
33 glucocorticoids Phase 3
34 BB 1101 Phase 3
35 Gastrointestinal Agents Phase 3
36 Hydrocortisone-17-butyrate Phase 3
37 Hydrocortisone 17-butyrate 21-propionate Phase 3
38
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
39
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
40
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
41
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
42
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
43
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
44
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
45
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
46
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
47
Sargramostim Approved, Investigational Phase 2 123774-72-1
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
49
Choline magnesium trisalicylate Approved Phase 2 64425-90-7 54682045
50
Lenalidomide Approved Phase 2 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
2 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
3 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
4 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
5 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
6 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
7 A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
8 A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
9 Efficacy and Safety of HVA Regimens as Salvage Treatment in Relapsed/Refractory (rr) Acute Myeloid Leukemia (AML) Completed NCT04424147 Phase 2
10 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) Completed NCT00305773 Phase 2 vorinostat
11 NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies Completed NCT01823198 Phase 1, Phase 2 Busulfan;Fludarabine Phosphate
12 A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
13 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
14 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
15 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
16 Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML) Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
17 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
18 A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
19 Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib
20 A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
21 Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
22 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
23 Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older Completed NCT00093418 Phase 2 tipifarnib
24 PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
25 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
26 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
27 A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
28 Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission Completed NCT00045435 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
29 Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML Completed NCT01235572 Phase 2
30 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
31 Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Completed NCT01361464 Phase 2 Tipifarnib
32 Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML Completed NCT01168219 Phase 2 Azacitidine;Busulfan;Fludarabine Phosphate;Methotrexate;Tacrolimus
33 Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. "7+3" for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML) Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
34 Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies Recruiting NCT04083170 Phase 2 Fludarabine;Cyclophosphamide;Thiotepa
35 A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS) Active, not recruiting NCT00392353 Phase 1, Phase 2 Azacitidine;Vorinostat
36 A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia Active, not recruiting NCT00658814 Phase 2 Azacitidine;Gemtuzumab Ozogamicin
37 A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
38 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Terminated NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus;Fludarabine
39 Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
40 Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia Terminated NCT00673153 Phase 2 gemtuzumab ozogamicin;vorinostat
41 OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age Terminated NCT02029417 Phase 2 cytarabine;omacetaxine mepesuccinate;decitabine
42 A Phase 2 Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia With Mutated Nucleophosmin-1 Terminated NCT02030405 Phase 2 Ixazomib
43 Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML. Terminated NCT01607645 Phase 2 decitabine;idarubicin;cytarabine
44 A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission Terminated NCT00089388 Phase 2 cilengitide
45 Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study Terminated NCT01521936 Phase 2
46 Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study Terminated NCT01342887 Phase 1, Phase 2 cyclosporine;pravastatin sodium;mitoxantrone hydrochloride;etoposide
47 A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission Terminated NCT01465386 Phase 2 bortezomib
48 Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission Withdrawn NCT00101140 Phase 2 anti-thymocyte globulin;fludarabine phosphate;thiotepa
49 A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene Withdrawn NCT01835288 Phase 2 arsenic trioxide
50 Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia Completed NCT00101296 Phase 1 tipifarnib

Search NIH Clinical Center for Acute Erythroid Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Erythroid Leukemia cell therapies at LifeMap Discovery.

Genetic Tests for Acute Erythroid Leukemia

Genetic tests related to Acute Erythroid Leukemia:

# Genetic test Affiliating Genes
1 Acute Myeloid Leukemia, M6 Type 28

Anatomical Context for Acute Erythroid Leukemia

Organs/tissues related to Acute Erythroid Leukemia:

MalaCards : Myeloid, Bone Marrow, Bone, Nk Cells, Spleen, Endothelial, T Cells

Publications for Acute Erythroid Leukemia

Articles related to Acute Erythroid Leukemia:

(show top 50) (show all 5436)
# Title Authors PMID Year
1
Synthetic flavagline derivative 1-chloroacetylrocaglaol promotes apoptosis in K562 erythroleukemia cells through miR-17-92 cluster genes. 62
36216575 2022
2
Improving MR cell size imaging by inclusion of transcytolemmal water exchange. 62
35794795 2022
3
Enhancing the biological properties of zinc complexes with bis(indolyl)methane groups: Synthesis, characterization, DNA interaction, and biocide activity. 62
36027843 2022
4
UM171 cooperates with PIM1 inhibitors to restrict HSC expansion markers and suppress leukemia progression. 62
36335089 2022
5
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases. 62
36323674 2022
6
DNA methylation status of DNAJA4 is essential for human erythropoiesis. 62
36420716 2022
7
The accumulation of miR-125b-5p is indispensable for efficient erythroblast enucleation. 62
36270980 2022
8
[Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation]. 62
36208236 2022
9
Triphenyltin(IV) dithiocarbamate compound induces genotoxicity and cytotoxicity in K562 human erythroleukemia cells primarily via mitochondria-mediated apoptosis. 62
35963475 2022
10
A comprehensive study of p53 protein. 62
36183376 2022
11
11H-Benzo[4,5]imidazo[1,2-a]indol-11-one as a New Precursor of Azomethine Ylides: 1,3-Dipolar Cycloaddition Reactions with Cyclopropenes and Maleimides. 62
36361988 2022
12
Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1. 62
36246167 2022
13
Grab regulates transferrin receptor recycling and iron uptake in developing erythroblasts. 62
35820059 2022
14
Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds. 62
36157733 2022
15
Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in RUNX1 deficiency. 62
35839075 2022
16
Biological Evaluation of 3-Azaspiro[Bicyclo[3.1.0]Hexane-2,5'-Pyrimidines] as Potential Antitumor Agents. 62
36142688 2022
17
Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. 62
35839275 2022
18
HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia. 62
35871293 2022
19
EloA promotes HEL polyploidization upon PMA stimulation through enhanced ERK1/2 activity. 62
34697988 2022
20
Biological Role of the Intercellular Transfer of Glycosylphosphatidylinositol-Anchored Proteins: Stimulation of Lipid and Glycogen Synthesis. 62
35806423 2022
21
LRF Promotes Indirectly Advantageous Chromatin Conformation via BGLT3-lncRNA Expression and Switch from Fetal to Adult Hemoglobin. 62
35806029 2022
22
[Hypoxia promotes erythroid differentiation of human K562 cells by upregulating endothelial PAS domain-containing protein 1 (EPAS1) expression]. 62
35732606 2022
23
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. 62
35421216 2022
24
Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation. 62
34117374 2022
25
Frequency of complete remission after standard 3+7 induction therapy in patients with acute myeloid leukemia. 62
35799743 2022
26
Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression. 62
35578888 2022
27
Pre-mRNA splicing factor U2AF2 recognizes distinct conformations of nucleotide variants at the center of the pre-mRNA splice site signal. 62
35524551 2022
28
FLI1 regulates inflammation-associated genes to accelerate leukemogenesis. 62
35104574 2022
29
Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation. 62
35181392 2022
30
Flumioxazin, a PPO inhibitor: A weight-of-evidence consideration of its mode of action as a developmental toxicant in the rat and its relevance to humans. 62
35367320 2022
31
Erythroid differentiation in mouse erythroleukemia cells depends on Tmod3-mediated regulation of actin filament assembly into the erythroblast membrane skeleton. 62
35195928 2022
32
Quantifying RNA synthesis at rate-limiting steps of transcription using nascent RNA-sequencing data. 62
35036951 2022
33
GAPDH is involved in the heme-maturation of myoglobin and hemoglobin. 62
34972240 2022
34
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. 62
35179961 2022
35
Detachment of Hexokinase II From Mitochondria Promotes Collateral Sensitivity in Multidrug Resistant Chronic Myeloid Leukemia Cells. 62
35719932 2022
36
Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia. 62
35140839 2022
37
[Molecular pathogenesis and therapeutic targets in acute erythroid leukemia]. 62
35264503 2022
38
Treatment of acute erythroleukaemia with high-dose cytarabine in a cat with feline leukaemia virus infection. 62
34599794 2022
39
Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases. 62
35975117 2022
40
A Rare STXBP2 Mutation in Severe COVID-19 and Secondary Cytokine Storm Syndrome. 62
35207437 2022
41
BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. 62
34435481 2021
42
Involvement of autophagy in diosgenin‑induced megakaryocyte differentiation in human erythroleukemia cells. 62
34458927 2021
43
The Y14-p53 regulatory circuit in megakaryocyte differentiation and thrombocytopenia. 62
34816104 2021
44
Identification of Spiro-Fused Pyrrolo[3,4-a]pyrrolizines and Tryptanthrines as Potential Antitumor Agents: Synthesis and In Vitro Evaluation. 62
34769424 2021
45
Use of Stingless Bee Propolis and Geopropolis against Cancer-A Literature Review of Preclinical Studies. 62
34832943 2021
46
Sildenafil Citrate Downregulates PDE5A mRNA Expression in Women with Recurrent Pregnancy Loss without Altering Angiogenic Factors-A Preliminary Study. 62
34768607 2021
47
Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders. 62
34426256 2021
48
Modular Synthesis and Antiproliferative Activity of New Dihydro-1H-pyrazolo[1,3-b]pyridine Embelin Derivatives. 62
34681250 2021
49
Transcriptomic profile of human erythroleukemia cells in response to Sargassum fusiforme polysaccharide and its structure analysis. 62
34688468 2021
50
Multifunctional protein 4.1R regulates the asymmetric segregation of Numb during terminal erythroid maturation. 62
34364872 2021

Variations for Acute Erythroid Leukemia

Expression for Acute Erythroid Leukemia

Search GEO for disease gene expression data for Acute Erythroid Leukemia.

Pathways for Acute Erythroid Leukemia

GO Terms for Acute Erythroid Leukemia

Biological processes related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 10.13 NPTN JAK2 GATA2 GATA1
2 positive regulation of miRNA transcription GO:1902895 9.97 GATA2 MYB SPI1
3 positive regulation of erythrocyte differentiation GO:0045648 9.91 TAL1 GATA2 GATA1
4 vascular wound healing GO:0061042 9.84 GATA2 CD34
5 myeloid cell apoptotic process GO:0033028 9.81 GATA1 EPO
6 hemopoiesis GO:0030097 9.8 TAL1 GATA2 EPOR CD34
7 negative regulation of hematopoietic progenitor cell differentiation GO:1901533 9.78 MYB GATA2
8 erythropoietin-mediated signaling pathway GO:0038162 9.76 EPOR EPO
9 regulation of primitive erythrocyte differentiation GO:0010725 9.71 GATA1 GATA2
10 basophil differentiation GO:0030221 9.67 GATA1 TAL1
11 eosinophil fate commitment GO:0035854 9.62 GATA1 GATA2
12 embryonic hemopoiesis GO:0035162 9.55 TAL1 IL3 GATA1
13 erythrocyte differentiation GO:0030218 9.47 TAL1 SPI1 MYB KLF1 JAK2 GATA1
14 myeloid cell differentiation GO:0030099 9.26 TAL1 JAK2 GATA2 GATA1

Molecular functions related to Acute Erythroid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.32 TAL1 SPI1 GATA2 GATA1 CD34

Sources for Acute Erythroid Leukemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....